MIRM — Mirum Pharmaceuticals Inc. stock price and chart

Share this page

MIRM

$80.14-2.73%

as of close, Oct 16, 2026

☾ AH $80.14 -2.73%

Mirum Pharmaceuticals Inc.Stock · HealthcareRussell 2000 0.2%Nasdaq Composite 0.01%US Stock Market 0.008%Russell 3000 0.007%

PeersMRNALLYMDTUNHJNJTMO

Technical analysis2

Overlay lines0

Addendum charts0

Available history since Jul 23, 2019

VolumeEEEE

20192021202320242026

20.040.060.080.0100.0120.005.0M10.0M$80.14

2026-10-16

Price$80.14

MA20$100.51

MA50$98.45

Vol2.0M

What would $1,000 invested in MIRM be worth today? →

MIRM returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $80.14
YTD price return: +1.46%
YTD total return: +1.46%
Next earnings: Nov 3, 2026
Market cap: 5.2B2019-09 231.3M2026-10 5.2B+2151.4% over the window
Enterprise value: 4.8B
Shares outstanding: 64.9M2019-06 23M2026-06 64.9M+182.4% over the window
52W low: $63.23
52W high: $130.00
From 52W high: -38.35%
From 52W low: +26.74%
52W range: 25%

Volume

Rel volume: 0.56×
30D volume: 829.9K
30D $ vol: 73.3M

Fundamentals

Sales (ttm): 618.1M2020-12 02026-06 618.1M
Sales/share: $9.522020-12 $0.002026-06 $9.52
EPS (ttm): -$14.912021-06 -$5.062026-06 -$14.91+194.8% over the window
FCF (ttm): -228.7M2019-12 -39.6M2026-06 -228.7M+477.0% over the window
FCF/share: -$3.522019-12 -$1.562026-06 -$3.52+125.6% over the window
Book value/share: -$0.162019-06 -$1.522026-06 -$0.16-89.4% over the window
Net margin: -139.18%2021-06 -1392.1%2026-06 -139.2%-90.0% over the window
ROA: -82.32%2019-12 -35.8%2026-06 -82.3%+129.8% over the window
Current ratio: 2.862019-06 7.642026-06 2.86-62.6% over the window

Growth (CAGR, ttm) · 10Y

Sales: +44.05%2025-06-30 → 2026-06-30429.2M → 618.1M (+44.0% total)+74.75%2023-06-30 → 2026-06-30115.8M → 618.1M (+433.8% total)+123.86%2021-06-30 → 2026-06-3011M → 618.1M (+5518.8% total)n/a
Shares: +29.27%2025-06-30 → 2026-06-3050.2M → 64.9M (+29.3% total)+19.24%2023-06-30 → 2026-06-3038.3M → 64.9M (+69.5% total)+16.30%2021-06-30 → 2026-06-3030.5M → 64.9M (+112.8% total)n/a

Per-share growth (CAGR, ttm) · 10Y

Sales/share: +11.43%2025-06-30 → 2026-06-30$8.54 → $9.52 (+11.4% total)+46.55%2023-06-30 → 2026-06-30$3.02 → $9.52 (+214.9% total)+92.48%2021-06-30 → 2026-06-30$0.36 → $9.52 (+2540.6% total)n/a
Price: +7.69%2025-10-16 → 2026-10-16$74.42 → $80.14 (+7.7% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+42.16%2023-10-16 → 2026-10-16$27.89 → $80.14 (+187.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+36.15%2021-10-15 → 2026-10-16$17.12 → $80.14 (+368.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.n/a
Total return: +7.69%2025-10-16 → 2026-10-16$74.42 → $80.14 (+7.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+42.16%2023-10-16 → 2026-10-16$27.89 → $80.14 (+187.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+36.15%2021-10-15 → 2026-10-16$17.12 → $80.14 (+368.1% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.n/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: -5.4×2019-12 -11.852026-10 -6.05-48.9% over the window
Fwd P/E: -251.1×
P/S (ttm)Market cap ÷ TTM revenue.: 8.4×2021-06 47.972026-10 8.42-82.4% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: -499.3×2019-09 1.582026-10 -499.61-31682.7% over the window
EV/Sales (ttm): 7.7×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: -4.40%2019-12 -6.4%2026-06 -3.0%-52.7% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 64.9M ÷ 50.2M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -29.27%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-29.27%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($2.6B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -29.27%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($5.2B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.00%2019-12 0.0%2026-06 0.0%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($5.2B). Same caveat as the cash buyback yield.: 0.00%2019-12 0.0%2026-06 0.0%

Vs own 10Y history

P/S: 36th
P/B: 100th

Bar = where today’s multiple sits in MIRM’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-16#

-2.73%

-6.82%

-17.70%

-31.71%

YTD

+1.46%

+7.69%

+368.11%

Financial statements

Open full MIRM financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+10.48%	+0.43%
JNJ	Johnson & Johnson	-4.38%	+0.90%
ABBV	AbbVie Inc.	+8.73%	+0.71%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+6.97%	-1.29%
MRK	Merck & Co. Inc.	+0.72%	+0.52%
NVS	Novartis AG	+8.59%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+6.41%	-0.93%
AMGN	Amgen Inc.	+14.92%	-0.35%

MIRM — Mirum Pharmaceuticals Inc. price, chart and key statistics